From the Department of Nuclear Medicine, West China Hospital, Sichuan University.
Department of Nuclear Medicine, Chengdu Fifth People's Hospital, Chengdu.
Clin Nucl Med. 2023 Sep 1;48(9):763-767. doi: 10.1097/RLU.0000000000004758. Epub 2023 Jun 29.
This multicenter study was designed to evaluate the relationship between preablation thyroglobulin antibody (TgAb) positivity and clinical outcomes in pediatric patients with papillary thyroid carcinoma (PTC).
In the period 2005-2020, all consecutive PTC patients 18 years or younger who underwent total thyroidectomy and radioiodine ablation at 3 tertiary hospitals in southwestern China were retrospectively included. Thyroglobulin antibody was measured before remnant ablation. Tumor characteristics and long-term outcomes were compared between TgAb-positive and TgAb-negative patients.
One hundred thirty-two patients were analyzed. Preablation TgAb positivity was presented in 37.1% of patients. Tumor characteristics, lymph node metastases, and median duration of follow-up were similar between TgAb-positive and -negative patients. During follow-up, the percentage of patients with either surgical reintervention for lymph node metastases (4.1% vs 4.8%, P = 1.000) or repeated 131 I therapy (14.3% vs 20.5%, P = 0.373) was similar between TgAb-positive and -negative patients. At the final follow-up visit, the rates of structural disease did not differ between the 2 groups (6.1% vs 4.8%, P = 0.710).
This multicentric study highlights no association of preablation TgAb positivity and clinical outcome in pediatric patients with PTC.
本多中心研究旨在评估甲状腺球蛋白抗体（TgAb）阳性与儿童甲状腺乳头状癌（PTC）患者消融前临床结局的关系。
2005 年至 2020 年期间，回顾性纳入在中国西南部 3 家三级医院行全甲状腺切除术和放射性碘消融的所有 18 岁及以下的连续 PTC 患者。在残余消融前测量甲状腺球蛋白抗体。比较 TgAb 阳性和 TgAb 阴性患者的肿瘤特征和长期结局。
共分析了 132 例患者。37.1%的患者在消融前存在 TgAb 阳性。TgAb 阳性和阴性患者的肿瘤特征、淋巴结转移和中位随访时间相似。在随访期间，因淋巴结转移而再次手术干预（4.1%比 4.8%，P=1.000）或重复 131I 治疗（14.3%比 20.5%，P=0.373）的患者比例在 TgAb 阳性和阴性患者之间相似。在最后一次随访时，两组结构性疾病的发生率无差异（6.1%比 4.8%，P=0.710）。
这项多中心研究表明，儿童 PTC 患者消融前 TgAb 阳性与临床结局无关。
